Drug intelligence / Profile preview

SDextran1

Development stage: Preclinical
Modality: Small Molecules
Administration: Ophthalmic, Intravenous, Parenteral

Overview

SDextran1 is a sulfated dextran with a molecular weight of 1000 Da. It functions as a selective blocker of aldolase A (ALDOA), an enzyme known to promote the growth of hepatocellular carcinoma (HCC). By inhibiting ALDOA, SDextran1 has demonstrated significant anti-HCC effects both in vitro and in vivo.

Targets

ALDO (Fructose-bisphosphate aldolase A)

Beyond the preview

Go deeper on SDextran1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDextran1.

Explore the full profile